CHARLOTTESVILLE, Virginia, September 9 Biovista Inc.today announced that BVA-201, its drug targeting Multiple Sclerosis (MS), hasshown significant positive results in the MOG-induced Experimental AllergicEncephalomyelitis (EAE) murine model of MS. BVA-201 is an existing drug thatBiovista repositioned in MS and is aimed at neuroprotection. It was shown tohave both efficacy in reducing symptoms and no toxic effects in this wellestablished model of MS.
"This is our second success in MS in a period of 6 months, with BVA-201showing efficacy levels closely comparable to those of dexamethasone," saidAris Persidis, Ph.D., President of Biovista. "Histology results are alsoencouraging, since they seem to confirm our expectations regarding thecompound's mechanism of action. What is even more important is that BVA-201has a known and very favorable safety profile and is already approved forchronic use," Dr. Persidis added.
For a non-confidential information pack on BVA-201 contact Biovista email@example.com.
About Biovista's BVA-201 trial in the MS EAE-MOG model
MS is a chronic inflammatory neurological disease. It is the mostfrequent non-traumatic disabling neurologic disease among young adults, withover 2.5 million patients worldwide. In the animal proof-of-concept trial,BVA-201 was compared to dexamethasone, a potent anti-inflammatory andimmunosuppressive drug that is efficient in accelerating the recovery from MSrelapses but too toxic for chronic use. BVA-201 induced a statisticallysignificant reduction of EAE severity, the magnitude of which was directlycomparable to that caused by dexamethasone. Furthermore, BVA-201 protectedneural axons and myelin against degeneration, as shown in the histologyanalysis performed. This analysis provided strong evidence that the compoundworks as a neuroprotective agent as opposed to most currently approved drugsthat target the immune system.
About Biovista's repositioning pipeline and technology platform
Biovista applies high-throughput discovery efforts to finding solutionsfor commercially relevant, unmet medical needs. Biovista's proprietaryrepositioning technology allows the company's experts to performmechanism-of-action based analyses and systematically assess clinicaloutcomes in any therapeutic area of interest, at relatively low cost and veryshort time spans. The company is presently using this platform to develop itsown pipeline of repositioned drugs in areas such as CNS, cardiovasculardisease, oncology and auto-immune diseases.For more information, please contact: Dr Aris Persidis Biovista, Inc. +1-434-242-6514 firstname.lastname@example.org
SOURCE Biovista Inc.